Centre Cuts Prices Of 35 Essential Medicines
The formulations, which will now cost less, span a wide range of medicines including anti-inflammatory, cardiovascular, antibiotic, anti-diabetic and psychiatric medicines.
The Ministry of Chemicals and Fertilisers notified the order based on price regulation by the NPPA. The price reductions, which apply across drugs, are expected to bring relief to consumers, particularly those managing chronic conditions.
The key formulations covered by the price control order include fixed-dose combinations of Aceclofenac, Paracetamol and Trypsin Chymotrypsin, Amoxycillin and Potassium Clavulanate, Atorvastatin combinations and newer oral anti-diabetic combinations like Empagliflozin, Sitagliptin, and Metformin.
The price of one Aceclofenac-Paracetamol-Trypsin Chymotrypsin tablet manufactured by Akums Drugs & Pharmaceuticals and marketed by Dr Reddy's Laboratories has now been fixed at Rs 13, while the same formulation marketed by Cadila Pharmaceuticals is now priced at Rs 15.01.
Similarly, a tablet containing Atorvastatin 40 mg and Clopidogrel 75 mg, widely used for cardiovascular conditions, is priced at Rs 25.61.
Oral suspensions for paediatric use - Cefixime and Paracetamol combinations - have also been included, along with critical medications like Cholecalciferol drops for Vitamin D supplementation and Diclofenac Injection, which has been priced at Rs 31.77 per ml.
The official order states that retailers and dealers must display these updated price lists prominently in their premises. Failure to comply with the notified prices may attract penal provisions under the DPCO, 2013, and the Essential Commodities Act, 1955, including recovery of overcharged amounts with interest.
The NPPA clarified that the prices fixed were exclusive of Goods and Services Tax (GST), which may be added, if applicable. Manufacturers are required to comply with all statutory requirements, issue updated price lists in Form V through the Integrated Pharmaceutical Database Management System and submit the information to the NPPA and state drug controllers.
Any prior price orders issued for the specified formulations and manufacturers stand superseded by this latest notification.
The NPPA, which functions under the Ministry of Chemicals and Fertilisers, is the drug price regulator in India, responsible for fixing and revising prices of pharmaceutical products and monitoring the prices of both controlled and decontrolled drugs.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Standard
an hour ago
- Business Standard
Global Health standalone net profit rises 57.83% in the June 2025 quarter
Sales rise 44.27% to Rs 882.16 crore Net profit of Global Health rose 57.83% to Rs 151.96 crore in the quarter ended June 2025 as against Rs 96.28 crore during the previous quarter ended June 2024. Sales rose 44.27% to Rs 882.16 crore in the quarter ended June 2025 as against Rs 611.45 crore during the previous quarter ended June 2024. Particulars Quarter Ended Jun. 2025 Jun. 2024 % Var. Sales 882.16611.45 44 OPM % 22.0621.64 - PBDT 212.07153.04 39 PBT 178.66129.74 38 NP 151.9696.28 58
Business Standard
2 hours ago
- Business Standard
Artemis Medicare Services Ltd Reports Robust Q1 FY26 Results with 28.2% Growth in Net Profit
VMPL Gurugram (Haryana) [India], August 7: Artemis Medicare Services Ltd. has announced robust performance for Q1 for financial year 2025-26, with a consolidated gross revenue of ₹2,681 million for Q1, an upturn of 14.4% year on year. The Board of Directors were pleased to have approved the financial results for the quarter ended June 30, 2025, showing steady performance on all metrics. The company's net revenue from operations went up by 14.2% to ₹2,550 million from ₹2,232 million in the first quarter of FY25. The company's EBITDA went up 19.0% to ₹483 million, with a good margin of 19.0%. Most importantly, net profit jumped 28.2% to ₹212 million, up from ₹165 million in the same quarter last year. Quarterly Artemis Hospital Gurgaon Performance Highlights Q1 FY2025-26 (Apr-Jun) vs Q1 FY2024-25 * Average gross revenue per occupied bed (ARPOB) was at Rs 83,900, as against Rs 79,200 * Net Revenue from operations was up 16.0% to close at Rs 2,412 Million, as against Rs 2,080 Million in Q1 FY25 * EBITDA reported was Rs 495 Million at a margin of 20.5%, as against Rs 415 Million * Bed capacity utilisation stood at 61.2% * Revenues from overseas patients increased by 31.4% to Rs 704 Million from Rs 536 Million * Overseas patients contributed 29% to Net Revenue * Average length of stay (ALOS) at 3.7 days compared to 3.6 days Quarterly Consolidated Performance Highlights Q1 FY2025-26 (Apr-Jun) vs Q1 FY2024-25 * Net Revenue from operations was up 14.2% to close at Rs 2,550 Million, as against Rs 2,232 Million in Q1 FY25 * EBITDA reported was Rs 483 Million at a margin of 19.0%, as against Rs 406 Million * Net profit for Q1 closed at Rs 212 Million, as against Rs 165 Million in the Q1 FY25 Artemis Hospital in Gurgaon also delivered impressive results. The hospital's net income went up 16.0% to ₹2,412 million. The average revenue per occupied bed (ARPOB) went up to ₹83,900, the highest it has ever been. In Q1 FY25, it was ₹79,200. EBITDA for the hospital went up to ₹495 million, keeping a margin of 20.5%. Overseas sales were a big part of this, going up by 31.4% to ₹704 million, which is 29% of net sales. The average length of stay (ALOS) was 3.7 days, and 61.2% of the beds were full. Commenting on the company's performance, Onkar Kanwar, Chairman, Artemis Medicare Services Ltd said "We are pleased to announce a strong start to FY26, with Q1 delivering consistent growth and resilient operational performance despite being a seasonally soft quarter. Our continued focus on cost optimization, operational efficiency, and disciplined execution has enabled us to maintain healthy profitability and margins. Our highest-ever ARPOB, driven by an optimized case and payer mix and strong international patient inflow, reinforces our position as a leader in Medical Value Travel. During the quarter, we added new beds at our flagship hospital's third tower, strengthening capacity and improving unit economics in the coming quarters. We also signed a binding MoU with Dr. Vidya Sagar Kaushalya Devi Memorial Health Centre for a proposed Medical Services Agreement, marking an important step in expanding in North India. On the clinical front, we launched India's first private Geriatrics & Longevity Department and partnered with KIMS, Hyderabad for heart-lung transplants, underscoring our commitment to advanced patient-centric care. Looking ahead, we remain focused on sustainable growth through operational excellence, geographic expansion and strategic partnerships, as we continue building Artemis into one of India's most trusted healthcare brands."
NDTV
2 hours ago
- NDTV
Considering Freezing Your Eggs? Nutritionist Tells All You Need To Know
Egg freezing is a process where a woman's unfertilized eggs are retrieved and stored in liquid nitrogen for future use in an In Vitro Fertilization (IVF) procedure. Thinking about freezing your eggs? You're not alone. With more women delaying parenthood and prioritising their careers, egg freezing has become an increasingly popular option for those looking to preserve their fertility. But what exactly is egg freezing, and how does it work? Egg freezing, or oocyte cryopreservation, is a process where a woman's unfertilized eggs are retrieved, rapidly cooled, and stored in liquid nitrogen for future use in an In Vitro Fertilization (IVF) procedure. The process involves taking fertility hormones to stimulate the ovaries to produce multiple eggs, which are then surgically extracted and frozen using a technique called vitrification to preserve their viability for many years. Later, when a woman is ready to conceive, the eggs can be thawed, fertilized with sperm to create embryos, and then implanted into the uterus. According to nutritionist Rashi Chowdhary, egg freezing is one of the most empowering decisions you make for yourself and your future self. In a video shared on Instagram, she says, "It gives you options, time and a sense of control especially when you aren't ready for it just yet. It often takes more than one cycle so, it's an financial and emotional investment. The success rate will always vary depending on your age and your health." View this post on Instagram A post shared by Rashi Chowdhary (@rashichowdhary) Things you need to know 1. Timeline While timelines may differ somewhat, the full egg freezing procedure should take two to three weeks to finish. Most cycles take less than two weeks to complete. 2. Expense Medication and egg retrieval are included in the usual Rs 1.5 lakh to Rs 2 lakh cost of egg freezing. The annual storage fees are between Rs 30,000 and Rs 40,000. Other procedures, including injecting the sperm and embryo culture, come under embryo freezing. These might cost anything between Rs 2 lakh and Rs 2.5 lakh. 3. Right time to freeze your eggs Anytime under the age of 30 is the best time for freezing high-quality eggs with a high success rate. Between the ages of 30 to 35, there is still a strong window but the quality of the eggs starts to dip. You can also freeze your eggs after the age of 35, but it may require additional considerations. Disclaimer: This content including advice provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your doctor for more information. NDTV does not claim responsibility for this information.
